2303 - REVIVE

Go Back to BMT CTN Protocol Listing

  • Protocol Number and Short Name: 2303 REVIVE
  • Protocol Long Name: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of remestemcel-L-rknd added to ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease
  • Synopsis
  • FAQs
  • Key Personnel
    • BMT CTN 2303 Co-Chair: John Levine, MD
    • BMT CTN 2303 Co-Chair: Iskra Pusic, MD
    • BMT CTN 2303 Protocol Officer: Mehdi Hamadani, MD
    • BMT CTN 2303 Emmes Team: bmtctn2303@emmes.com 
    • BMT CTN 2303 Unblinded Team: 2303_unblinded@emmes.com
  • Keywords: Graft vs. Host Disease, GVHD, Graft versus Host Disease, Ryoncil, remestemcel-L, remestemcel-L-rknd, mesenchymal stromal cells, MSC, Ruxolitinib, Steroid Refractory, Steroid-Refractory, GVHD Treatment